|
US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6344321B1
(en)
*
|
1990-06-11 |
2002-02-05 |
Gilead Sciences, Inc. |
Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
|
|
US6346611B1
(en)
*
|
1990-06-11 |
2002-02-12 |
Gilead Sciences, Inc. |
High affinity TGfβ nucleic acid ligands and inhibitors
|
|
US6229002B1
(en)
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
AU2004242462B2
(en)
*
|
1999-07-29 |
2008-01-24 |
Gilead Sciences, Inc. |
Nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor C-Met and to integrins
|
|
PT2070939E
(pt)
|
2001-05-25 |
2014-06-09 |
Univ Duke |
Moduladores de agentes farmacológicos
|
|
US7879991B2
(en)
*
|
2002-05-06 |
2011-02-01 |
Noxxon Pharma Ag |
CGRP binding nucleic acids
|
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
|
EP1552002A4
(en)
*
|
2002-06-18 |
2006-02-08 |
Archemix Corp |
APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE
|
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040253243A1
(en)
*
|
2003-01-21 |
2004-12-16 |
David Epstein |
Aptamer therapeutics useful in ocular pharmacotherapy
|
|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US8039443B2
(en)
*
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
WO2006050498A2
(en)
|
2004-11-02 |
2006-05-11 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
EP1620547B1
(en)
|
2003-04-21 |
2014-06-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040219663A1
(en)
*
|
2003-04-30 |
2004-11-04 |
Page Robert D. |
Biopolymer array fabrication using different drop deposition heads
|
|
US7727969B2
(en)
*
|
2003-06-06 |
2010-06-01 |
Massachusetts Institute Of Technology |
Controlled release nanoparticle having bound oligonucleotide for targeted delivery
|
|
NZ592039A
(en)
*
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
HUE050481T2
(hu)
|
2004-02-12 |
2020-12-28 |
Archemix Llc |
Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
EP1756138A4
(en)
*
|
2004-03-05 |
2009-07-01 |
Archemix Corp |
APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES
|
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
|
US20080214489A1
(en)
*
|
2004-04-19 |
2008-09-04 |
Anthony Dominic Keefe |
Aptamer-mediated intracellular delivery of oligonucleotides
|
|
US7579450B2
(en)
*
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
AU2005282380A1
(en)
*
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
|
JP2008512098A
(ja)
|
2004-09-07 |
2008-04-24 |
アーケミックス コーポレイション |
フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
|
|
AU2006226192A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
|
US20090075342A1
(en)
*
|
2005-04-26 |
2009-03-19 |
Sharon Cload |
Metabolic profile directed aptamer medicinal chemistry
|
|
AU2006265896B2
(en)
|
2005-06-30 |
2012-05-31 |
Archemix Corp. |
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
JP2009513135A
(ja)
|
2005-10-28 |
2009-04-02 |
プリーシス・ファーマシューティカルズ・インコーポレイテッド |
エンコードされたライブラリーを用いて興味のある化合物を同定する方法
|
|
US7922000B2
(en)
*
|
2006-02-15 |
2011-04-12 |
Miraial Co., Ltd. |
Thin plate container with a stack of removable loading trays
|
|
DK1991275T3
(en)
|
2006-03-08 |
2014-12-08 |
Archemix Llc |
Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
|
|
WO2008150495A2
(en)
*
|
2007-06-01 |
2008-12-11 |
Archemix Corp. |
Vwf aptamer formulations and methods for use
|
|
US20080305157A1
(en)
*
|
2007-06-08 |
2008-12-11 |
University Of Maryland Office Of Technology Commercialization |
Encapsulation and separation of charged organic solutes inside catanionic vesicles
|
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
|
US8207298B2
(en)
*
|
2008-05-01 |
2012-06-26 |
Archemix Corp. |
Methods of separating biopolymer conjugated molecules from unconjugated molecules
|
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
GB0904957D0
(en)
|
2009-03-23 |
2009-05-06 |
Univ Erasmus Medical Ct |
Tumour gene profile
|
|
GB0915515D0
(en)
|
2009-09-04 |
2009-10-07 |
Ucl Business Plc |
Treatment of vasculoproliferative conditions
|
|
US8841429B2
(en)
*
|
2009-11-03 |
2014-09-23 |
Vivonics, Inc. |
Nucleic acid ligands against infectious prions
|
|
US8236570B2
(en)
|
2009-11-03 |
2012-08-07 |
Infoscitex |
Methods for identifying nucleic acid ligands
|
|
SI2558577T1
(sl)
|
2010-04-16 |
2019-05-31 |
Nuevolution A/S |
Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
|
|
GB201013573D0
(en)
|
2010-08-12 |
2010-09-29 |
Ucl Business Plc |
Treatment
|
|
GB201013785D0
(en)
|
2010-08-17 |
2010-09-29 |
Ucl Business Plc |
Treatment
|
|
GB201014026D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucl Business Plc |
Treatment
|
|
WO2012038744A2
(en)
|
2010-09-22 |
2012-03-29 |
Genome Research Limited |
Detecting mutations
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
GB201120711D0
(en)
|
2011-12-01 |
2012-01-11 |
Univ Erasmus Medical Ct |
Method for classifying tumour cells
|
|
EP2802659A1
(en)
|
2012-01-10 |
2014-11-19 |
Noxxon Pharma AG |
Nucleic acids specifically binding cgrp
|
|
CA2866696A1
(en)
|
2012-03-09 |
2013-09-12 |
Ucl Business Plc |
Treatment of cancer
|
|
CA2868096C
(en)
|
2012-03-28 |
2019-12-31 |
Somalogic, Inc. |
Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
|
|
GB201205739D0
(en)
|
2012-03-30 |
2012-05-16 |
Ucl Business Plc |
Treatment of acute inflammation in the respiratory tract
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
SI4374873T1
(sl)
|
2013-07-12 |
2026-01-30 |
Astellas Us Llc |
Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
|
|
ES2834910T3
(es)
|
2013-09-09 |
2021-06-21 |
Somalogic Inc |
Aptámeros de PDGF y VEGF que tienen una estabilidad mejorada y su uso en el tratamiento de enfermedades y trastornos mediados por PDGF y VEGF
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
CN106456542A
(zh)
|
2014-03-17 |
2017-02-22 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于局部递送的适体
|
|
US9605266B2
(en)
|
2014-07-16 |
2017-03-28 |
City Of Hope |
Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore
|
|
EP3206719B1
(en)
|
2014-10-15 |
2020-04-08 |
City of Hope |
Rna aptamers against transferrin receptor (tfr)
|
|
KR102854749B1
(ko)
|
2015-11-18 |
2025-09-04 |
에스아이오2 메디컬 프로덕츠, 엘엘씨 |
안과 제제용 제약 패키지
|
|
US20180326126A1
(en)
|
2015-11-18 |
2018-11-15 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
CN108883172A
(zh)
|
2015-11-18 |
2018-11-23 |
福迈康股份公司 |
包含vegf拮抗剂的液体配制品的预填充药物包装
|
|
EP3407868A1
(en)
|
2016-01-26 |
2018-12-05 |
Formycon AG |
Liquid formulation of a vegf antagonist
|
|
GB201704953D0
(en)
|
2017-03-28 |
2017-05-10 |
Imp Innovations Ltd |
Natural killer cells
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
MX2020003695A
(es)
|
2017-11-30 |
2020-08-03 |
Arrakis Therapeutics Inc |
Fotosondas de union a acido nucleico y usos de las mismas.
|
|
GB201804514D0
(en)
|
2018-03-21 |
2018-05-02 |
Ucl Business Plc |
Treatment of pyroptosis
|
|
GB201804515D0
(en)
|
2018-03-21 |
2018-05-02 |
Takayuki Takakondo |
Treatment of necroptosis
|
|
GB201804922D0
(en)
|
2018-03-27 |
2018-05-09 |
Ucl Business Plc |
Traatment
|
|
EP4245862B1
(en)
*
|
2019-06-25 |
2025-01-15 |
Actome GmbH |
Method and kit for measuring of analytes in bi-component systems and uses thereof
|
|
GB202002711D0
(en)
|
2020-02-26 |
2020-04-08 |
Ucl Business Ltd |
Treatment
|
|
TWI916375B
(zh)
|
2020-06-25 |
2026-03-01 |
英商梅迪繆思有限公司 |
軸突損傷之預防
|
|
CA3192419A1
(en)
|
2020-09-15 |
2022-03-24 |
Adam Byrne |
Treatment of idiopathic pulmonary fibrosis
|
|
GB202017673D0
(en)
|
2020-11-09 |
2020-12-23 |
Imperial College Innovations Ltd |
Treatment of pulmonary arterial hypertensive
|
|
EP4475850A1
(en)
|
2022-02-09 |
2024-12-18 |
Imperial College Innovations Limited |
Treatment of telangiectasia
|
|
EP4581132A1
(en)
|
2022-09-02 |
2025-07-09 |
Imperial College Innovations Limited |
Natural killer cells
|
|
GB202303784D0
(en)
|
2023-03-15 |
2023-04-26 |
Institute Of Cancer Res Royal Cancer Hospital |
Cancer treatment
|
|
WO2024261477A1
(en)
|
2023-06-20 |
2024-12-26 |
Yaqrit Limited |
Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate
|
|
WO2026093738A1
(en)
|
2024-10-28 |
2026-05-07 |
Institute Of Cancer Research: Royal Cancer Hospital |
Cancer treatment
|